Facet Biotech

February 7, 2012

Monoclonal Antibody Companies Command Premiums

July 11, 2010 By MD Becker Partners Leave a Comment

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]

Filed Under: Articles Tagged With: Abbott, Abgenix, ABT, adalimumab, Agensys, Alexion Pharmaceuticals, ALXN, Astellas Pharma, AstraZeneca, Avastin, Bayer Schering Pharma AG, BAYRY.PK, bevacizumab, biosimilars, BMY, Bristol-Myers Squibb, Cambridge Antibody Tech, CEPH, Cephalon, Ception Therapeutics, cetuximab, Domantis, Eli Lilly & Co, Erbitux, erlotinib, Facet Biotech, FDA, GEN.CO, Genmab A/S, GENZ, Genzyme, Herceptin, HGSI, Human Genome Sciences, Humira, ImClone Systems, IMGN, IMMU, ImmunoGen, Immunomedics, Inc., infliximab, KaloBios Pharmaceuticals, LLY, mAbs, MacroGenics, MedImmune, Micromet, MITI, monoclonal antibodies, MORG.DE, Morphosys AG, Morphotek, NASDAQ Biotechnology Index, NBI, NeuTec Pharma plc, OncoMed Pharmaceuticals, OSI Pharmaceuticals, PFE, Pfizer, Regeneron, REGN, Remicade, RHHBY, Rinat Neuroscience Corp, Rituxan, rituximab, roche, sanofi-aventis Group, Seattle Genetics, SGEN, SNY, Tarceva, trastuzumab, Tufts Center for the Study of Drug Development, XOMA

Biotech Baker’s Dozen to Watch at Hematology Meeting

November 29, 2009 By MD Becker Partners 2 Comments

The 51st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data from [...]

Filed Under: Articles Tagged With: AEterna Zentaris, AEZS, Allos Therapeutics, ALTH, American Society of Hematology, ARIA, ARIAD Pharmaceuticals, Calistoga Pharmaceuticals, CELG, Celgene, chemotherapeutics, CYCC, Cyclacel Pharmaceuticals, Facet Biotech, FACT, GENT, Gentium SPA, HDAC inhibitors, IMGN, ImmunoGen, KaloBios Pharmaceuticals, kerx, Keryx Biopharmaceuticals, kinase inhibitors, monoclonal antibodies, nucleoside analogues, ONXX, Onyx Pharmaceuticals, PCYC, Pharmacyclics, pi3k, proteasome inhibitors, sapacitabine, Seattle Genetics, Semafore Pharmaceuticals, SGEN, small modular immunopharmaceuticals, SNSS, Sunesis Pharmaceuticals, TRBN, Trubion Pharmaceuticals